RxDoctor Payments DataLook up a doctor →

Mark Scioli, MD

Orthopedic Surgery · Lubbock, TXNPI 1619971249

Payments from drug & device makers

$763,857in general payments, 2019–2025

Across 237 payments — averaging $3223.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • 4web, Inc.$704K
  • Globus Medical$48K
  • Johnson & Johnson$4K
  • Spineology Inc.$3K
  • Rattan And Associates$1K
  • Stryker$613
  • plus $3K from 27 others

What the payments were for

  • Royalty or licence$25,54136%
  • Consulting fees$27,99540%
  • Speaking & faculty fees$1,9503%
  • Travel & lodging$8,36612%
  • Food & beverage$5,0277%
  • Education$1,2002%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$763,857 in reported general payments places this provider in the 95th percentile of 33 orthopedic surgery providers in Texas.

See all orthopedic surgery providers in Texas

Medicare billing

Part B allowed, 2024
$292,630
Medicare patients
359
Services billed
3,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,535$40,651
Xtampza ErOxycodone Myristate11$25,816
Fentanyl131$15,615
LyricaPregabalin13$11,195
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen115$3,214
Pregabalin132$2,070
Tizanidine Hcl158$1,886
Morphine Sulfate ErMorphine Sulfate49$1,825
Methocarbamol235$1,783
Hydromorphone Hcl100$1,685
Oxycodone Hcl73$1,448
Tramadol Hcl153$1,333
Gabapentin102$1,219
Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen35$1,174
Meloxicam367$1,053

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$88$25,81611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 33 orthopedic surgery providers in Texas.

Other orthopedic surgery in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →